OBJECTIVE: To assess the effectiveness of an instructional program on heterogeneity designed for medical and pharmacy managers.
METHODS: A live educational program was offered to members of the Academy of Managed Care Pharmacy at the fall 2012 educational meeting and also to medical directors and managers attending a national payer roundtable meeting in October 2012. Participants completed a retrospective pretest-posttest assessment of their knowledge, attitudes, and selfefficacy immediately following the program. Participants were offered the opportunity to participate in a follow-up assessment 6 months later. Willing participants for the follow-up assessment were contacted via e-mail and telephone. Rasch rating scale models were used to compare pre-and postscores measuring participants' knowledge about and attitude towards heterogeneity.
RESULTS: A total of 49 individuals completed the retrospective pretestposttest assessment and agreed to be a part of the program evaluation. Fifty percent (n = 25) of participants had heard of the phrase "heterogeneity of treatment effect," and 36 (72%) were familiar with the phrase "individualized treatment effect" prior to the live program. Participants reported a significant improvement in knowledge of heterogeneity (P < 0.01) and attitudes about heterogeneity (P < 0.01) immediately after attending the program. At the time of the educational program, participants had either never considered heterogeneity (26%) or reported not knowing (28%) whether their organizations considered it when determining basic coverage. Participants were more likely to report "sometimes" considering heterogeneity for determining necessity for individual appeals, prior authorization, tier placement for pharmaceutical therapies, and other types of medical management. At the 6-month follow-up, 21 of the 49 willing participants (43% response rate) completed the evaluation; participants continued to have a good understanding of heterogeneity, but there was no significant difference in attitudes towards heterogeneity between pre-and 6-month follow-up.
CONCLUSION: A live educational program was effective in improving participants' immediate knowledge and attitudes regarding the topic of heterogeneity. Participating managed care pharmacists and medical managers indicated that heterogeneity of treatment effect was likely to be used in determining prior authorizations and determining necessity.
• Heterogeneity of treatment effect is nonrandom variability in response to treatment and includes benefits as well as harms.
• The theory of reasoned action (TRA) and its extension, the theory of planned behavior (TRB), suggest that a particular behavior is more likely to occur if (a) a person has a favorable attitude, a belief that valued others do it, a strong intention to perform it, and the knowledge, experience, and perceived ability to do so (self-efficacy); (b) there is no serious environmental constraint preventing performance; and (c) the behavior is considered salient.
• Although applications of TRA and TPB have focused primarily on predicting patient behavior, several studies suggest that they have predictive value for uptake of clinician-targeted instructional interventions.
• No previous studies have been reported that have examined the impact of an educational program on heterogeneity. Numerous studies have documented the benefit of educational programming on health professionals' knowledge and skill.
What is already known about this subject
• This program evaluation found that an educational session on heterogeneity was effective in improving participants' knowledge of heterogeneity concepts and methods to evaluate heterogeneity.
• Attendees reported significant improvements in attitudes and self-efficacy related to heterogeneity from prior to the program to immediately after the session.
what rate new ideas and technology spread through cultures.
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This educational program, designed for managed care medical and pharmacy directors and managers, was presented in conjunction with national medical and pharmacy conferences. Participants completed a brief retrospective, pretest-posttest evaluation to assess knowledge and attitudes regarding heterogeneity; participants also completed a 6-month follow-up evaluation to determine knowledge retention and application of heterogeneity concepts in managed care environments.
■■ Methods
The educational program on heterogeneity was 1 component of a larger programmatic evaluation. Briefly, the project included these 4 components: (1) a needs assessment via structured individual telephonic interviews; (2) a live and enduring educational program for MCO medical and pharmacy directors and managers on the topic of heterogeneity and comparative effectiveness evidence; (3) a brief retrospective pretest-posttest evaluation of medical and pharmacy directors and managers' knowledge of and attitudes toward heterogeneity and comparative effectiveness evidence; and (4) a follow-up evaluation of medical and pharmacy directors and managers' self-efficacy in interpreting heterogeneity.
Educational Program on Heterogeneity
The CME/CE program on heterogeneity and comparative effectiveness evidence was designed specifically for MCO medical and pharmacy directors and managers; the program content was based on the results from focus group interviews and modeled after the comparative effectiveness research (CER) workshops developed previously by the investigators. The program was offered at 2 different venues in October 2012: the Academy of Managed Care Pharmacy (AMCP) Educational Conference in Cincinnati, Ohio, and a national payor roundtable (NPR) meeting in Dallas, Texas. A total of 100 individuals (AMCP = 84; NPR = 16) attended the 2 programs. The interactive program was designed to include a dynamic mix of instructional methods that included didactic lecture, case studies, practice with a heterogeneity evaluation checklist, small-group problem-based learning sessions, and brief periodic self-assessments. Cognitive learning strategies during the live program involved rehearsal, elaboration, organization, and comprehension monitoring. 12, 13 Presentations were independently developed by participating faculty, and they had full control of program content. Attendees received a copy of the program materials that included presentations, reference materials, and accompanying resources for future use. The activities and supplemental readings were designed to provide opportunities for attendees to achieve deeper comprehension and improved skills to facilitate application and adoption of these newly learned concepts in their organizations. the virus, 2 dosing of aminoglycosides based on renal function, 3 or the likelihood of a serious drug-drug interaction based on patient genotype. 4 Training and how to assess or evaluate the statistical and clinical relevance of these differences has historically been limited. It is imperative that medical and pharmacy managers possess relevant knowledge to determine the extent that heterogeneity was evaluated in clinical trials. In the case of meta-analysis, they need to be able to ascertain whether (a) data should have been combined statistically; (b) appropriate statistical procedures (e.g., sensitivity analysis) were employed; and (c) selection bias was assessed.
Comparing evidence between pharmacotherapies entails numerous nuances, such as populations studied, severity of disease, analytical procedures, and reporting of results, to name a few. While means of central tendency is helpful in informing some health care decisions, there is potential for misinterpretation if applied indiscriminately. 5, 6 Therefore, recognizing the drawbacks to applying population means ("average effects") to individual patients or groups who differ from the population average can help improve decision making. 7 Heterogeneity with respect to meta-analysis is often considered problematic because it suggests that pooling across studies is potentially inappropriate, yet true heterogeneity is likely informative. 8 Heterogeneity of treatment effects reflects patient diversity in risk of disease, responsiveness to treatment, and vulnerability to adverse effects. 7 By recognizing these factors, decision makers can make better use of evidence. 7, 8 While medical and pharmacy managers in managed care organizations (MCOs) have excelled at strategies to apply current best evidence to manage benefits for their members, they have generally lacked an in-depth understanding and appreciation of heterogeneity in the context of comparative effectiveness evidence and individual response to drug therapy. To appropriately evaluate pharmacotherapies, these health care decision makers need a solid understanding of heterogeneity and its implications. Furthermore, they must possess the knowledge and skills to critically evaluate the evidence to make informed decisions. Previous studies have demonstrated that physicians and pharmacists receive relatively little formal training in evidence synthesis and statistics through medical and pharmacy curricula. 9 Jonas and Crotty (2009) specifically call for "short courses at national meetings" addressing comparative methods. 10 This program evaluation involved development and evaluation of a continuing medical (CME)/continuing education (CE) program, entitled "The Good, the Bad, and the Different: Deciphering Heterogeneity," created by the Comparative Effectiveness Research Group at the University of Arizona. The goal was to improve attendees' knowledge, attitudes, and self-efficacy concerning heterogeneity and its impact on comparative effectiveness evidence based on Rogers' diffusion of innovation theoretical framework. 11 The diffusion of innovation model is a theory that seeks to explain how, why, and at
Initial Retrospective Pretest-Posttest Knowledge and Attitudinal Evaluation
At the end of the training program, participants were asked to complete a retrospective pretest-posttest self-evaluation. The evaluation instrument was designed to assess participants' self-reported knowledge and attitudes concerning heterogeneity and its impact on comparative effectiveness evidence and their perceived ability to use this evidence. The knowledge evaluation asked attendees to report their ability to assess heterogeneity across studies, within studies, across individual patients, and within individuals. The attitudinal evaluation asked participants to express their opinions as to whether (a) understanding heterogeneity will help them improve patient care, (b) they are confident they could use information on heterogeneity in their organization, (c) they are knowledgeable about heterogeneity assessment methods, and (d) they have an understanding of meta-analysis approaches.
The retrospective pretest-posttest evaluation was given at the end of the program and asked the participants to reflect on their knowledge and attitudes prior to the program. This particular evaluation design was selected to help limit constructshift bias, a phenomenon that may occur when the internal construct changes as a result of the experience. [14] [15] [16] [17] Others have reported the usefulness of this assessment design in supporting validity when measuring knowledge and attitude changes. [18] [19] [20] [21] [22] The evaluation contained 4 knowledge and 4 attitudinal items. A 5-point Likert scale was used for each item with semantic differential response choices appropriate for the stem question. Knowledge item-anchors included "poor," "fair," "good," "very good," and "excellent." Attitudinal item anchors included "strongly disagree," "disagree," "neither agree or disagree," "agree," and "strongly agree." Table 1 provides a listing of the evaluation items included on the questionnaire.
Consideration of Heterogeneity in Making Formulary Decisions
Participants were asked how often they considered heterogeneity when setting medical policy or determining medical necessity for individual appeals, prior authorization, tiering of pharmaceutical treatments, and other types of medical management. These items were only asked after the educational session (i.e., a retrospective pretest-posttest was not used for this section of the questionnaire). Item anchors included "never," "sometimes," "usually," "always," and "don't know."
Six-Month Follow-up
Participants were asked to complete a follow-up 6 months later to determine if long-term maintenance of knowledge and attitude is achievable after attending the educational program. The evaluation instrument was distributed online via a website link (http://cer.pharmacy.arizona.edu). This evaluation included all of the initial items plus 2 new items. The new items were 23 In order to use the Rasch model, the rating scales were assessed for proper function. The Wolfe and Chiu procedure was used to compare item and person values on pretest and posttest. 24 When measuring pretestposttest change with a Rasch rating scale, the Wolf and Chiu procedure is used as an anchoring technique and in interpreting data using a retrospective pretest-posttest data collection technique. [24] [25] When construct shift was identified between pre-and postknowledge items, item-anchoring was performed as per the Wolf and Chiu procedure. Z-tests were performed to identify content gaps and construct shift. STATA 12 was used to calculate t-tests for evaluating retrospective pretest and posttest Rasch transformed data. Because follow-up responses were anonymous, independent group t-tests were conducted to compare follow-up responses with those measurements taken at the completion of the educational program. An a priori alpha of 0.05 for the Type I error rate was established for all statistical tests for significance. This was a program evaluation; therefore, it did not meet the federal definition of research, and institutional review board approval was not required as per university guidance.
■■ Results Familiarity with Heterogeneity Terms
Fifty of the 100 pharmacists and medical directors and managers (50% response rate) completed the initial evaluations (participation in the study was voluntary). Of those completing the evaluation instruments, 46 (92%) were pharmacists, and 4 (8%) were physicians. The 6-month follow-up was sent to only those attendees who indicated they were employed by a managed care or health provider organization and who agreed to be contacted (n = 49). Twenty-one persons completed the 6-month follow-up.
The first question on the retrospective pretest-posttest selfevaluation asked participants to indicate whether they had heard of the phrases "heterogeneity of treatment effect" or "individualized treatment effect" before attending the training program. Twenty-five (50%) respondents had heard of the former terminology, and 36 (72%) had heard of the latter phrase.
Knowledge and Attitudinal Items
Group means for participants (n = 49) responding to the retrospective pretest-posttest evaluation, expressed as number and percentage, are shown in figures 1 and 2 (raw data). Once the "excellent" and "very good" categories were merged with the "good" category, proper rating scale function was achieved; the final knowledge rating scaled used anchors of "poor, "fair," and "good." No construct shift was identified between pre-and postknowledge items. Rasch analysis indicated that after attending the program, participants reported statistically significant improvements across all knowledge items (P < 0.01 for all comparisons). The raw data for changes in attitudes toward and confidence in using heterogeneity and related concepts are shown in Figure 2 . For the attitudinal section of the instrument, once the "strongly disagree" and "disagree" were merged, and "strongly agree" and "agree" were merged, proper rating scale function was achieved; the final knowledge rating scaled used anchors of "disagree, "neither agree nor disagree," and "agree." Construct shift was identified, and item anchoring was used. Statistical evaluations conducted on the Rasch transformed data indicated that participants were significantly more likely to agree with the heterogeneity attitudinal items after attending the program (P < 0.01 for all items). Overall, participants were significantly more likely to agree with or rate their abilities as higher after completing the CME/CE program.
Consideration of Heterogeneity in Making Formulary Decisions
Participants were asked on the retrospective pretest-posttest evaluation how often they considered heterogeneity when setting medical policy. In general, responses varied considerably with each item (e.g., basic coverage, determination of necessity for individual appeals, etc.). Because this set of questions was asked only once, only descriptive results will be presented. Descriptive results are displayed in Figure 3 . At the time of the educational program, 54% of participants either never considered heterogeneity (26%) or reported not knowing (28%) whether they considered it when determining basic coverage. However, 44% (n = 22) of participants reported either 
■■ Discussion
In this program evaluation, we demonstrated that a heterogeneity educational session significantly improved short-term self-reported knowledge and attitudes on the topic among participants. The knowledge gain was largely sustained over time. The educational program included oral presentations, group discussions, and activity-based workshops to communicate knowledge and skills. However, based on the comments, participants indicated they learned most from lectures. Thus, a lecture with both verbal and visual elements appears to be an effective method to changing MCO medical and pharmacy directors and managers' short-term selfperceived knowledge and attitudes regarding heterogeneity. The other forms of instructional strategies may be used as supplementary techniques.
Before attending the training program, the majority of respondents indicated they had heard the phrase "heterogeneity of treatment effect" or "individualized treatment effect" (50% and 72%, respectively). This suggests that participants had some degree of knowledge of heterogeneity particularly regarding individual heterogeneity; this is understandable given that health care providers are trained to incorporate individual factors to optimize drug efficacy and safety.
In terms of evaluating evidence and developing policies, some participants reported thinking about issues of heterogeneity in practice, but most respondents did not consider heterogeneity when making formulary decisions unless more information was available. Participants reported being concerned about the overall cost of health care and the need for pharmacogenomics testing before approving coverage of certain drugs or ordering additional tests or identifying high-risk populations.
In this program evaluation, we compared changes between self-reported pre-and post-training session knowledge and attitude on both the group and individual levels. When comparing perceived knowledge and attitudes, attitude changed less from pre-to post-training session. That is, those who attended the CE session had an overall positive attitude toward heterogeneity. This is understandable because the individuals who attended the training self-selected and would therefore be more likely to want to learn about heterogeneity. sometimes (26%) or usually (18%) considering heterogeneity in their basic coverage decisions. Participants were more likely to report "sometimes" considering heterogeneity for determining necessity for individual appeals, prior authorization, tier placement for pharmaceutical therapies, and other types of medical management. Thirteen (26%) participants mentioned thoughts or concerns, including the need for pharmacogenomics testing before coverage of certain drugs or ordering additional tests and identifying high-risk populations.
Participant Assessment of the Educational Program
Participant assessment of the education program was measured on the retrospective pretest-posttest evaluation by asking which activities contributed most to learning. Most respondents (n = 31, 62%) indicated that the 2-hour lecture was the component from which they learned the most, followed by group activities for case studies (10%). Some comments mentioned that the lecturers' teaching approach and style were effective, enjoyable, and memorable both verbally and visually. But group activities were not as effective or appreciated by the audience, which may be due to the complexity and unfamiliarity with the topic.
Participant Follow-up Assessment
As previously mentioned, 21 attendees of the educational program responded to the request to participate in a follow-up assessment on the topic of heterogeneity. Regarding knowledge with the concepts of heterogeneity, 95% of respondents indicated they had a clear understanding of the phrase "heterogeneity of treatment effect" after 6 months, with 14.3% rating their knowledge as "very good"; 61.9% rated it as "good"; and 19.1% indicated it was "average." Five respondents indicated that their organizations had made decisions regarding coverage of a medical therapy that was due, in part, to differences across or within patients. For example, a respondent commented that he/she made formulary decisions on various HIV medications based on heterogeneity within studies as well as documented diagnosis of patients.
Rasch analysis indicated that significant differences between attitudes towards heterogeneity were not observed between pre-and 6-month follow-up except that respondents indicated they were more knowledgeable about heterogeneity methods at 6 months as compared with before the workshop (P = 0.002).
Instrument Validity and Reliability
Each component (knowledge and attitude) of the retrospective pretest-posttest evaluation instrument was evaluated using Rasch techniques as already described. Furthermore, the participant separation index for the knowledge scale (i.e., the extent that items are sufficiently spread out to define distinct levels of ability) translated to person reliability of 0.78 and 0.59 (analogous to Cronbach's alpha). The Cronbach's alpha Authors tified during analysis. Examples for additional question items could be "I am confident in my ability to use heterogeneity" or "I feel confident in my ability to use concepts of heterogeneity for coverage decisions."
The program evaluation also has some limitations in sampling process and response rate. There were very few medical directors and managers (8%) who participated in the evaluation, so the results might not fully represent the entire sample of attendees present at the program. The study had a moderate number of participants (100), a moderate response rate (50%) for pre-and postevaluation, and a moderate response rate (43%) for follow-up. Higher response rates are preferred to ensure that the responses are reflective of the entire sample of individuals who attended the program.
■■ Conclusion
The heterogeneity education provided to pharmacists and medical directors and managers in this program evaluation increased knowledge of heterogeneity. Participants demonstrated significant improvement in knowledge and attitudes (P < 0.01) immediately after attending the program. The continuing education maintained these changes with good understanding of heterogeneity over 6 months.
There were some theoretical content gaps identified in the attitudinal instrument. This can be explained by Bloom's Taxonomy, a learning theory that emphasizes skills in the cognitive domain revolving around knowledge, comprehension, and critical thinking on a particular topic. 26 The 6 levels in the taxonomy are hierarchically ordered from the easiest to most difficult. Bloom's Taxonomy was used in designing the educational program in order to provide participants with a more valuable learning experience. When using Bloom's Taxonomy to explain our results, it can be seen that participants feel that it is more difficult to apply heterogeneity issues than it is to recognize them. Knowledge questions in this evaluation were primarily on the knowing/understanding level (the lowest level), while the attitudinal questions were mostly on the comprehension and application level (higher level) in Bloom's Taxonomy. This program evaluation also evaluated whether long-term maintenance of knowledge and attitude was achieved after attending a CME/CE educational program on heterogeneity. Bloom's Taxonomy may offer some explanations for this as well. Knowledge (the easiest concepts) was maintained over time, while some of the more difficult concepts (attitude and application) were not. Perhaps these more difficult concepts require reinforcement in order to be maintained over the long term.
Heterogeneity is a complex topic. Additional research concerning educational tactics to improve knowledge/attitudes regarding heterogeneity warrants further study. Beyond appraising study quality and applicability, a thorough understanding of heterogeneity is essential for full appreciation of the implications of evidence for clinical practice. Along with growing interest in CER, there is increasing complexity in conducting and interpreting such evidence. [27] [28] [29] Health decision makers can use evidence from various methods, including randomized controlled trials, observational studies, and syntheses of existing evidence (e.g., systematic reviews with or without meta-analsysis).
Limitations
The content validity suggests that the current questions lack enough variation among knowledge items and that there are gaps among attitudinal items. This suggests more items with different levels of difficulty are needed to fill in item gaps in the evaluation instrument. Bloom's Taxonomy 28 suggests learning is a process of moving up a hierarchy and that people begin with the memory of a knowledge followed by achieving new knowledge in deeper levels of understanding. 12 In this way, many instruments can be improved, and ours is no different. The heterogeneity knowledge questions in our evaluation instrument could increase explanatory power by the addition of more difficult and easy questions (questions on the extremes of the knowledge spectrum). Attitudinal questions could also be added to improve the attitudinal content gap that was iden- Study concept and design were contributed by Malone, Hines, Hurwitz, with assistance by Brown. Taylor, Brown, Hines, and Hurwitz collected data, which were interpreted by Dean, Hilgaertner, Malone, and Warholak. The manuscript was written by Dean, Hilgaertner, Malone, and Warholak and revised by Taylor, Malone, and Warholak.
